Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.71 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.43 |
| ▸ | ACP1 | P24666 | 3/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077410 | 0.99 | HRH3 (0.69) | HRH3DHODHHTR2ACHRNA7KCNH2 | |
| SCHEMBL5074317 | 0.94 | HRH3 (0.62) | HRH3DHODHHTR2A | |
| SCHEMBL5072007 | 0.93 | HRH3 (0.61) | HRH3DHODHHTR2AADRA2AADRA2B | |
| SCHEMBL5253215 | 0.85 | HRH3 (0.66) | HRH3HTR2ACHRNA7KCNH2ACP1 | |
| SCHEMBL5420818 | 0.83 | HRH3 (1.00) | HRH3BACE1 | |
| SCHEMBL5416885 | 0.82 | HRH3 (0.98) | HRH3 | |
| SCHEMBL5076379 | 0.82 | HRH3 (0.48) | HRH3DHODHHTR2ACHRNA7 | |
| SCHEMBL5074314 | 0.81 | HRH3 (0.63) | HRH3DHODHKCNH2 | |
| SCHEMBL5250172 | 0.80 | HRH3 (0.59) | HRH3DHODHHTR2AKCNH2ADRA2A | |
| SCHEMBL5074332 | 0.80 | HRH3 (0.47) | HRH3DHODHCHRNA7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | claimed |
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7041675-B2 | Heterocyclic compounds and their use as PARP inhibitors | ABBOTT GMBH & CO. KG (DE) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | PARP1, PARP2, PARP12 | HRH3 625/4885DHODH 4220/4885HTR2A 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.